{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T20:59:42Z","timestamp":1789851582750,"version":"4.0.1"},"reference-count":9,"publisher":"Centers for Disease Control MMWR Office","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MMWR Morb. Mortal. Wkly. Rep."],"DOI":"10.15585\/mmwr.mm7303a2","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T10:11:10Z","timestamp":1706177470000},"page":"57-61","source":"Crossref","is-referenced-by-count":25,"title":["Underuse of Antiviral Drugs to Prevent Progression to Severe COVID-19 \u2014 Veterans Health Administration, March\u2013September 2022"],"prefix":"10.15585","volume":"73","author":[{"given":"Paul A.","family":"Monach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia T.","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathanael R.","family":"Fillmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"La","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Westyn","family":"Branch-Elliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6224","published-online":{"date-parts":[[2024,1,25]]},"reference":[{"key":"key-10.15585\/mmwr.mm7303a2-202401250758-R1","unstructured":"National Institutes of Health. Coronovirus disease 2019 (COVID-19) treatment guidelines. Washington, DC: US Department of Health and Human Services, National Institutes of Health; 2023. https:\/\/www.covid19treatmentguidelines.nih.gov\/"},{"key":"key-10.15585\/mmwr.mm7303a2-202401250758-R2","unstructured":"National Institutes of Health. COVID-19 treatment guidelines: anti-SARS-CoV-2 monoclonal antibodies. Washington, DC: US Department of Health and Human Services, National Institutes of Health; 2023. https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/antivirals-including-antibody-products\/anti-sars-cov-2-monoclonal-antibodies\/"},{"key":"key-10.15585\/mmwr.mm7303a2-202401250758-R3","unstructured":"CDC. COVID-19. Interim clinical considerations for COVID-19 treatment in outpatients. Atlanta, GA: US Department of Health and Human Services, CDC; 2023. Accessed February 10, 2023.  https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/clinical-care\/outpatient-treatment-overview.html"},{"key":"key-10.15585\/mmwr.mm7303a2-202401250758-R4","unstructured":"Infectious Diseases Society of America. IDSA guidelines on the treatment and management of patients with COVID-19. Arlington, VA: Infectious Diseases Society of America; 2021. https:\/\/www.idsociety.org\/practice-guideline\/covid-19-guideline-treatment-and-management\/#null"},{"key":"key-10.15585\/mmwr.mm7303a2-202401250758-R5","doi-asserted-by":"publisher","first-page":"e2331249","DOI":"10.1001\/jamanetworkopen.2023.31249","article-title":"Anti\u2013SARS-CoV-2 pharmacotherapies among nonhospitalized US veterans, January 2022 to January 2023.","volume":"6","author":"Yan","year":"2023","journal-title":"JAMA Netw Open"},{"key":"key-10.15585\/mmwr.mm7303a2-202401250758-R6","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.15585\/mmwr.mm7143a2","article-title":"Racial and ethnic disparities in outpatient treatment of COVID-19\u2014United States, January\u2013July 2022.","volume":"71","author":"Boehmer","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.mm7303a2-202401250758-R7","article-title":"VA COVID-19 shared data resource","author":"US Department of Veterans Affairs","year":"2020"},{"key":"key-10.15585\/mmwr.mm7303a2-202401250758-R8","doi-asserted-by":"publisher","first-page":"e2240037","DOI":"10.1001\/jamanetworkopen.2022.40037","article-title":"Factors associated with severe COVID-19 among vaccinated adults treated in US Veterans Affairs Hospitals.","volume":"5","author":"Vo","year":"2022","journal-title":"JAMA Netw Open"},{"key":"key-10.15585\/mmwr.mm7303a2-202401250758-R9","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/S0140-6736(22)01656-7","article-title":"Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales.","volume":"400","author":"Agrawal","year":"2022","journal-title":"Lancet"}],"container-title":["MMWR. Morbidity and Mortality Weekly Report"],"original-title":[],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T10:11:24Z","timestamp":1706177484000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cdc.gov\/mmwr\/volumes\/73\/wr\/mm7303a2.htm?s_cid=mm7303a2_w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":9,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,1,25]]}},"URL":"https:\/\/doi.org\/10.15585\/mmwr.mm7303a2","relation":{"is-referenced-by":[{"id-type":"doi","id":"10.1186\/s12982-025-01192-3","asserted-by":"object"}]},"ISSN":["0149-2195","1545-861X"],"issn-type":[{"value":"0149-2195","type":"print"},{"value":"1545-861X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1,25]]},"published":{"date-parts":[[2024,1,25]]}}}